PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.56%
Positive revenue growth while MRVL is negative. John Neff might see a notable competitive edge here.
145.36%
Positive gross profit growth while MRVL is negative. John Neff would see a clear operational edge over the competitor.
136.55%
Positive EBIT growth while MRVL is negative. John Neff might see a substantial edge in operational management.
136.55%
Positive operating income growth while MRVL is negative. John Neff might view this as a competitive edge in operations.
151.06%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
151.85%
EPS growth of 151.85% while MRVL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
151.85%
Diluted EPS growth of 151.85% while MRVL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-2.09%
Share reduction while MRVL is at 0.84%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
1.64%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-46.88%
Negative OCF growth while MRVL is at 41.33%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-340.52%
Negative FCF growth while MRVL is at 47.49%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
500.98%
10Y revenue/share CAGR under 50% of MRVL's 1036.96%. Michael Burry would suspect a lasting competitive disadvantage.
64.54%
5Y revenue/share CAGR under 50% of MRVL's 206.06%. Michael Burry would suspect a significant competitive gap or product weakness.
44.33%
3Y revenue/share CAGR at 50-75% of MRVL's 72.14%. Martin Whitman would question if the firm lags behind competitor innovations.
165.97%
10Y OCF/share CAGR under 50% of MRVL's 3394.12%. Michael Burry would worry about a persistent underperformance in cash creation.
544.73%
5Y OCF/share CAGR is similar to MRVL's 569.44%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
-52.03%
Negative 3Y OCF/share CAGR while MRVL stands at 189.01%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
278.30%
Below 50% of MRVL's 1953.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
765.55%
5Y net income/share CAGR above 1.5x MRVL's 394.37%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-11.23%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1541.41%
10Y equity/share CAGR 1.25-1.5x MRVL's 1337.19%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
119.46%
5Y equity/share CAGR above 1.5x MRVL's 49.76%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
72.89%
3Y equity/share CAGR above 1.5x MRVL's 26.91%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.54%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
21.22%
Inventory growth well above MRVL's 3.86%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.86%
Negative asset growth while MRVL invests at 0.56%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.61%
We have a declining book value while MRVL shows 2.50%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.26%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-2.22%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.